NCT05391750 2026-02-17Venetoclax and Tocilizumab for the Treatment of Patients With Relapsed or Refractory t(11;14) Multiple MyelomaEmory UniversityPhase 1 Active not recruiting7 enrolled
NCT06042725 2025-12-24MC210808 Venetoclax in Combination With Lenalidomide and Dexamethasone (Ven-Rd), Daratumumab and Dexamethasone (Ven-Dd), or Daratumumab-Lenalidomide-Dexamethasone (Ven-DRd) for the Treatment of Multiple MyelomaMayo ClinicPhase 1 Recruiting100 enrolled
NCT03399539 2024-11-04Venetoclax, Ixazomib Citrate, and Dexamethasone in Treating Patients with Relapsed Multiple MyelomaMayo ClinicPhase 1 Completed8 enrolled
NCT03530683 2024-09-03A Clinical Trial to Learn About the Study Medicine Called Maplirpacept (PF-07901801), Alone and When Used in Combination With Other Medicines to Treat Participants With Advanced Hematological Malignancies, Including Lymphoma, Leukemia and Multiple MyelomaPfizerPhase 1 Terminated189 enrolled
NCT03878524 2024-03-04Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME TrialOHSU Knight Cancer InstitutePhase 1 Terminated2 enrolled
NCT01794507 2021-08-02A Study Evaluating ABT-199 in Multiple Myeloma Subjects Who Are Receiving Bortezomib and Dexamethasone as Standard TherapyAbbViePhase 1 Completed66 enrolled
NCT02391480 2019-11-29A Study Evaluating the Safety and Pharmacokinetics of ABBV-075 in Subjects With CancerAbbViePhase 1 Completed128 enrolled
NCT02951117 2017-06-05A Study of Venetoclax and ABBV-838 Combination Therapy With Dexamethasone in Participants With Multiple Myeloma Whose Cancer Has Come Back or Had No Response to Recent Cancer TreatmentAbbViePhase 1 Withdrawn